Your browser doesn't support javascript.
loading
Drug-induced hallucination: a case/non case study in the french pharmacovigilance database
Abou Taam, Malak; Boissieu, Paul de; Breton, Alexandre; Trenque, Thierry; Abou Taam, Rola.
Affiliation
  • Abou Taam, Malak; Reims University Hospitals. Regional Center for Pharmacovigilance and Pharmacoepidemiology. Reims. France
  • Boissieu, Paul de; Reims University Hospitals. Regional Center for Pharmacovigilance and Pharmacoepidemiology. Reims. France
  • Breton, Alexandre; Reims University Hospitals. Regional Center for Pharmacovigilance and Pharmacoepidemiology. Reims. France
  • Trenque, Thierry; Reims University Hospitals. Regional Center for Pharmacovigilance and Pharmacoepidemiology. Reims. France
  • Abou Taam, Rola; Necker-Enfants Malades Hospital. Pulmonology and Allergy Service. Department Pediatrics. Paris. France
Eur. j. psychiatry ; 29(1): 21-32, ene.-mar. 2015. tab
Article in English | IBECS | ID: ibc-137513
Responsible library: ES1.1
Localization: BNCS
ABSTRACT
Background and

Objectives:

Hallucinations are sensory perceptions which occur without external stimuli. There are associated with psychiatric disease but also can be related to organic disease and drug or toxic exposure. The purpose of our study was to investigate the association between exposure to medications and the reporting of hallucinations using data from the spontaneous-reporting French Pharmacovigilance Database (FPVD).

Methods:

We used the case/noncase method in the FPVD. Cases were all the observations of hallucination with the LLT term "perception disturbances", registered into the FPVD from January 1985 to Jan 2013. Data were expressed as odds ratio (OR) with their 95% confidence intervals.

Results:

Among the 469,181 reports of adverse effects recorded between 1985 and 2013, 4, 086 are hallucinations. For about 50% of these hallucinations were experimented by patient older than 65 years old. A statistically significant OR was found with several medications included rasagiline (OR 17.6 [ 95% CI 10.4-29.8] zolpidem (OR 12.9 [95% CI 11.3 - 14.8]), methylphenidate (OR 9.3 [95% CI 5.9-14.6]) and baclofene (OR 5.4 [95% CI 3.7-7.8]). An increased risk of hallucinations was also observing with non central nervous system drugs, including ertapenem (OR 24.0 [95% CI 14.2-40.5]), voriconazole (OR 12.9 [95% CI 10.2-16.5] and valacyclovir (OR 9.1 [95% CI 6.9-11.9]).

Conclusions:

This pharmacoepidermiological study describes and association between drugs and hallucinations. This relationship involves not only some already suspected drugs but also other drugs less known to induce such an adverse reaction. Despite the mandatory limits of this kind of study, these data should lead to special precautions in patient at risk (AU)
RESUMEN
No disponible
Subject(s)

Full text: Available Collection: National databases / Spain Database: IBECS Main subject: Perceptual Disorders / Hallucinations Limits: Humans Language: English Journal: Eur. j. psychiatry Year: 2015 Document type: Article Institution/Affiliation country: Necker-Enfants Malades Hospital/France / Reims University Hospitals/France

Full text: Available Collection: National databases / Spain Database: IBECS Main subject: Perceptual Disorders / Hallucinations Limits: Humans Language: English Journal: Eur. j. psychiatry Year: 2015 Document type: Article Institution/Affiliation country: Necker-Enfants Malades Hospital/France / Reims University Hospitals/France
...